Identification

Name
Aluminium
Accession Number
DB01370  (DB11314)
Type
Small Molecule
Groups
Approved
Description

A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

Structure
Thumb
Synonyms
  • 13Al
  • Al
  • Aluminio
  • Aluminium
  • Aluminium atom
  • Aluminum
External IDs
C.I. 77000 / CI 77000 / E-173 / INS NO.173 / INS-173
Product Ingredients
IngredientUNIICASInChI Key
Aluminium phosphateF92V3S521O7784-30-7ILRRQNADMUWWFW-UHFFFAOYSA-K
Aluminum acetate80EHD8I43D139-12-8WCOATMADISNSBV-UHFFFAOYSA-K
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AstringentGel.008 mg/4mLTopicalCa Botana International2015-01-01Not applicableUs
Domeboro CoolingGel5 mg/mLTopicalMOBERG PHARMA NORTH AMERICA LLC2016-03-01Not applicableUs
GelfosGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2016-02-282016-04-05Us
Gelfos MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-04-182016-12-13Us
GelfoseGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Gelfose MGel61.9 g/100gOralBoryung Pharmaceutical Co., Ltd2015-03-082016-12-13Us
Humco Aluminum Acetate (Burrow)Liquid530 mg/mLTopicalHumco Holding Group. Inc.1998-03-252017-08-24Us
Pedi-Boro Soak PaksPowder, for solution615 mg/1TopicalPedinol Pharmacal, Inc.2013-01-15Not applicableUs
TriCalm Extra StrengthSolution3 mg/mLTopicalCosmederm Bioscience2015-03-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Buro-sol Otic SolutionAluminum acetate (0.5 %) + Benzethonium chloride (0.03 %)SolutionAuricular (otic)Glaxosmithkline Inc1986-12-312015-01-05Canada
Gelfos MAluminium phosphate (12.38 g/20g) + Dimethicone (.04 g/20g) + Magnesium Hydroxide (.4 g/20g)SuspensionOralBoryung Pharmaceutical Co., Ltd.2017-01-012017-04-14Us
Gelfos MAluminium phosphate (61.9 g/100g) + Dimethicone (.2 g/100g) + Magnesium Hydroxide (2 g/100g)GelOralBoryung Pharmaceutical Co., Ltd2016-02-282016-12-13Us
Gelfos MAluminium phosphate (12.38 g/20g) + Dimethicone (.04 g/20g) + Magnesium Hydroxide (.4 g/20g)GelOralBoryung Pharmaceutical Co., Ltd.2017-01-012017-01-18Us
Oti-solAluminum acetate (0.5 %) + Benzethonium chloride (0.03 %)SolutionAuricular (otic)Jamp Pharma CorporationNot applicableNot applicableCanada
Star-otic SolutionAluminum acetate (10 %) + Acetic acid (1.5 %)SolutionAuricular (otic)Stellar Pharmacal Corp1992-12-311997-05-30Canada
Categories
UNII
CPD4NFA903
CAS number
7429-90-5
Weight
Average: 26.9815
Monoisotopic: 26.981538441
Chemical Formula
Al
InChI Key
XAGFODPZIPBFFR-UHFFFAOYSA-N
InChI
InChI=1S/Al
IUPAC Name
alumane
SMILES
[Al]

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.

TargetActionsOrganism
USerotransferrinNot AvailableHuman
USodium/potassium-transporting ATPase subunit alpha-1
binder
Human
UKallikrein-1
inhibitor
Human
UAmyloid beta A4 proteinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminium.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAluminium may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineAluminium may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAluminium may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aluminium.Experimental, Illicit
AcepromazineAluminium can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAluminium can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Aluminium.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Aluminium.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminium.Approved
AlimemazineAluminium can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAluminium can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Aluminium.Approved
AmphetamineAluminium may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Aluminium.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Aluminium.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Aluminium.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Aluminium.Investigational
AtazanavirAluminium can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminium.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminium.Approved, Investigational
BenzphetamineAluminium may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Aluminium.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aluminium.Approved
BL-1020Aluminium can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aluminium.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminium.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Aluminium.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminium.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminium.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Aluminium.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aluminium.Approved, Vet Approved
ChlorphentermineAluminium may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineAluminium can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineAluminium can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineAluminium can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Aluminium.Approved, Investigational
CinoxacinAluminium can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Aluminium.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminium.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Aluminium.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Aluminium.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Aluminium.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Aluminium.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Aluminium.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminium.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminium.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminium.Approved
DasatinibAluminium can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aluminium.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Aluminium.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aluminium.Approved
DemeclocyclineAluminium can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Aluminium.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Aluminium.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Aluminium.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Aluminium.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminium.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Aluminium.Vet Approved
DexmethylphenidateAluminium can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineAluminium may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAluminium may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Aluminium.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Aluminium.Approved, Investigational
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Aluminium.Approved
Dipotassium phosphateAluminium can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineAluminium can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aluminium.Approved
EnoxacinAluminium can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Aluminium.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Aluminium.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aluminium.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Aluminium.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Aluminium.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminium.Approved
Ferric CarboxymaltoseAluminium can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateAluminium can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateAluminium can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminium.Approved
FleroxacinAluminium can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Aluminium.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminium.Approved
FlumequineAluminium can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Aluminium.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Aluminium.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminium.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Aluminium.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Aluminium.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Aluminium.Approved
FluphenazineAluminium can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Aluminium.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Aluminium.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Aluminium.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Aluminium.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminium.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminium.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Aluminium.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Aluminium.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminium.Approved, Investigational
GarenoxacinAluminium can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinAluminium can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aluminium.Approved, Investigational
GemifloxacinAluminium can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineAluminium may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinAluminium can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Aluminium.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Aluminium.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminium.Approved, Vet Approved
HydroxyamphetamineAluminium may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminium.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium.Approved, Investigational
Iofetamine I-123Aluminium may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronAluminium can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAluminium can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAluminium can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAluminium can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Aluminium.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aluminium.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aluminium.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aluminium.Approved
LevofloxacinAluminium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineAluminium may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Aluminium.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aluminium.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Aluminium.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Aluminium.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Aluminium.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Aluminium.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Aluminium.Approved, Investigational
MephedroneAluminium may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAluminium may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminium.Approved
MesoridazineAluminium can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineAluminium may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium.Approved, Vet Approved
MethotrimeprazineAluminium can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineAluminium may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueAluminium can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateAluminium can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminium.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium.Experimental
MidomafetamineAluminium may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineAluminium can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Aluminium is combined with Misoprostol.Approved
MMDAAluminium may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Aluminium.Approved, Vet Approved
MoricizineAluminium can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidAluminium can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAluminium can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Aluminium.Investigational
NemonoxacinAluminium can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aluminium.Approved, Investigational
NorfloxacinAluminium can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Aluminium.Investigational
Oxolinic acidAluminium can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Aluminium.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Aluminium.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aluminium.Approved
PazufloxacinAluminium can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinAluminium can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aluminium.Approved
PerazineAluminium can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineAluminium can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAluminium may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidAluminium can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidAluminium can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminium.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Aluminium.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Aluminium.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aluminium.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Aluminium.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminium.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminium.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Aluminium.Experimental, Investigational
ProchlorperazineAluminium can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAluminium can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAluminium can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropericiazineAluminium can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineAluminium can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinAluminium can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineAluminium may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAluminium may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Aluminium.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Aluminium.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Aluminium.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aluminium.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminium.Approved, Investigational
RitobegronAluminium may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinAluminium can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminium.Approved
RufloxacinAluminium can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aluminium.Approved
SitafloxacinAluminium can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateAluminium can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateAluminium can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminium.Approved
SparfloxacinAluminium can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminium.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Aluminium.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Aluminium.Approved
TemafloxacinAluminium can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiazinamAluminium can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineAluminium can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineAluminium can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineAluminium can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Aluminium.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Aluminium.Approved
TolevamerThe risk or severity of adverse effects can be increased when Aluminium is combined with Tolevamer.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Aluminium.Approved, Vet Approved
TriethylenetetramineAluminium can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineAluminium can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineAluminium can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAluminium can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium.Approved, Investigational, Nutraceutical
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Aluminium.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Aluminium.Approved
Food Interactions
Not Available

References

Synthesis Reference

Bela Czegledi, Mihaly Csovari, Miklos Erdelyi, Lajos Streker, Istvan Toth, Katalin Szabo nee Mogyorosi, Szilard Riederauer, Geza Szentgyorgyi, "Process for producing alumina and ferric oxide from aluminium carriers with high iron and silicon content." U.S. Patent US4366129, issued 1876.

US4366129
General References
Not Available
External Links
Human Metabolome Database
HMDB15456
KEGG Compound
C06264
PubChem Compound
5359268
PubChem Substance
46504765
ChemSpider
4514248
ChEBI
28984
Therapeutic Targets Database
DAP000467
PharmGKB
PA164760864
Wikipedia
Aluminium
ATC Codes
A02AB03 — Aluminium phosphate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionCondylomata Acuminata1
1CompletedPreventionPlasmodium Falciparum Malaria1
2CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2Not Yet RecruitingTreatmentMalaria caused by plasmodium vivax1
2Unknown StatusDiagnosticDermatitis, Contact1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentFevers / Plasmodium Infections1
3CompletedTreatmentMalaria in Pregnancy1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malaria caused by Plasmodium falciparum1
4CompletedTreatmentMalaria caused by Plasmodium falciparum1
4CompletedTreatmentPlasmodium Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
Not AvailableCompletedTreatmentPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
GelTopical.008 mg/4mL
SolutionAuricular (otic)
GelTopical5 mg/mL
GelOral
SuspensionOral
GelOral61.9 g/100g
LiquidTopical530 mg/mL
Powder, for solutionTopical615 mg/1
SolutionTopical3 mg/mL
GelTopical2 mg/mL
PowderTopical4866 mg/4.866g
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)2.375 g·cm −3Not Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9733
Caco-2 permeable+0.7354
P-glycoprotein substrateNon-substrate0.881
P-glycoprotein inhibitor INon-inhibitor0.9787
P-glycoprotein inhibitor IINon-inhibitor0.9858
Renal organic cation transporterNon-inhibitor0.9108
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.8145
CYP450 1A2 substrateNon-inhibitor0.8813
CYP450 2C9 inhibitorNon-inhibitor0.9392
CYP450 2D6 inhibitorNon-inhibitor0.9716
CYP450 2C19 inhibitorNon-inhibitor0.9571
CYP450 3A4 inhibitorNon-inhibitor0.9855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.882
Ames testNon AMES toxic0.9633
CarcinogenicityCarcinogens 0.664
BiodegradationReady biodegradable0.7326
Rat acute toxicity2.0135 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9547
hERG inhibition (predictor II)Non-inhibitor0.9746
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous post-transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a post-transition metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous post-transition metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous post-transition metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous post-transition metal
Molecular Framework
Not Available
External Descriptors
elemental aluminium (CHEBI:33629)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Nolte E, Beck E, Winklhofer C, Steinhausen C: Compartmental model for aluminium biokinetics. Hum Exp Toxicol. 2001 Feb;20(2):111-7. [PubMed:11327511]
  2. Nagaoka MH, Maitani T: Binding affinity of aluminium to human serum transferrin and effects of carbohydrate chain modification as studied by HPLC/high-resolution ICP-MS--speciation of aluminium in human serum. J Inorg Biochem. 2005 Sep;99(9):1887-94. [PubMed:16139893]
  3. Mizutani K, Mikami B, Aibara S, Hirose M: Structure of aluminium-bound ovotransferrin at 2.15 Angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2005 Dec;61(Pt 12):1636-42. Epub 2005 Nov 19. [PubMed:16301797]
  4. Beardmore J, Rugg G, Exley C: A systems biology approach to the blood-aluminium problem: the application and testing of a computational model. J Inorg Biochem. 2007 Sep;101(9):1187-91. Epub 2007 Jun 12. [PubMed:17629565]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Menz RI, Walker JE, Leslie AG: Structure of bovine mitochondrial F(1)-ATPase with nucleotide bound to all three catalytic sites: implications for the mechanism of rotary catalysis. Cell. 2001 Aug 10;106(3):331-41. [PubMed:11509182]
  2. Silva VS, Goncalves PP: The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. [PubMed:14507470]
  3. Amador FC, Santos MS, Oliveira CR: Lipid peroxidation and aluminium effects on the cholinergic system in nerve terminals. Neurotox Res. 2001 Jul;3(3):223-33. [PubMed:15111247]
  4. Kohila T, Parkkonen E, Tahti H: Evaluation of the effects of aluminium, ethanol and their combination on rat brain synaptosomal integral proteins in vitro and after 90-day oral exposure. Arch Toxicol. 2004 May;78(5):276-82. [PubMed:15254985]
  5. Kohila T, Tahti H: Effects of aluminium and lead on ATPase activity of knockout +/- mouse cerebral synaptosomes in vitro. Altern Lab Anim. 2004 Oct;32(4):361-7. [PubMed:15651920]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name
KLK1
Uniprot ID
P06870
Uniprot Name
Kallikrein-1
Molecular Weight
28889.425 Da
References
  1. De Sousa MO, Santoro MM, De Souza Figueiredo AF: The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. J Enzyme Inhib Med Chem. 2004 Aug;19(4):317-25. [PubMed:15558947]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transition metal ion binding
Specific Function
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
Gene Name
APP
Uniprot ID
P05067
Uniprot Name
Amyloid beta A4 protein
Molecular Weight
86942.715 Da
References
  1. Banks WA, Niehoff ML, Drago D, Zatta P: Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. Brain Res. 2006 Oct 20;1116(1):215-21. Epub 2006 Aug 30. [PubMed:16942756]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Zatta P, Dalla Via L, Di Noto V: Binding studies on aluminum(III)-albumin interaction. Arch Biochem Biophys. 2003 Sep 1;417(1):59-64. [PubMed:12921780]

Drug created on July 06, 2007 14:27 / Updated on December 01, 2017 17:36